Overview
Abemaxen 200 mg contains Abemaciclib, a highly selective small-molecule inhibitor of cyclin-dependent kinases 4 and 6 (CDK4 and CDK6). Manufactured by Everest Pharmaceuticals Ltd. and distributed internationally by Saif Pharma, Abemaxen is a targeted oncology breakthrough designed to arrest the replication cycle of cancer cells. This specific 200 mg strength is primarily utilized as a single-agent monotherapy for patients with Hormone Receptor-positive (HR+) and Human Epidermal Growth Factor Receptor 2-negative (HER2-) metastatic breast cancer whose disease has progressed following endocrine therapy and prior chemotherapy.
Therapeutic Applications
Abemaxen 200 mg is principally indicated for the following clinical setting:
Metastatic Breast Cancer Monotherapy: As a standalone treatment for adult patients with HR+/HER2- metastatic breast cancer whose disease has progressed following endocrine therapy and at least one prior chemotherapy regimen in the metastatic setting.
Flexible Dosing Alignment: Serves as a primary component in personalized oncology regimens where a higher single-tablet strength is required to meet precise patient dosing plans.
Abemaciclib functions at the molecular level to disrupt the proliferation pathways of cancer cells:
Kinase Inhibition: It selectively inhibits CDK4 and CDK6 enzymes, which are frequently hyperactivated in HR+ breast cancer cells.
Retinoblastoma Pathway Blockade: By blocking these kinases, Abemaxen prevents the phosphorylation of the Retinoblastoma (Rb) protein.
Cell Cycle Arrest: Without Rb phosphorylation, the cancer cell cannot transition from the G1 phase to the S phase of cell division. This effectively locks the cell cycle, leading to cellular senescence (permanent growth inactivation) or apoptosis (programmed cell death).
Pharmacokinetic Profile
Absorption: Displays a median time to maximum plasma concentration ($T_{max}$) of 4 to 6 hours. Absolute oral bioavailability is approximately 45%.
Distribution: Extensively bound to human plasma proteins (~96.3%). It is capable of penetrating the central nervous system (CNS).
Metabolism: Extensively metabolized in the liver primarily via the CYP3A4 enzyme pathway into major active metabolites (M2, M20, and M18).
Elimination: Cleared mainly through fecal excretion (~81%), with a minor amount eliminated in urine (~5%). The mean plasma elimination half-life is approximately 18.3 hours.
Dosage & Administration
Standard Monotherapy Dose: The recommended single-agent dose is 200 mg taken orally twice daily.
Instructions: Tablets must be swallowed whole. Do not break, crush, chew, or split the tablets before swallowing. It can be taken with or without food but should be maintained on a consistent morning and evening schedule (roughly 12 hours apart).
Vomiting or Missed Dose: If a patient misses a dose or vomits after ingestion, they should skip that dose and take the next one at its regular time. Do not double the dose to make up for a missed tablet.
Clinical Considerations & Safety
Diarrhea: This is the most common side effect and typically manifests within the first week of treatment. At the first sign of loose stools, patients should start antidiarrheal therapy (e.g., loperamide) and optimize fluid intake.
Neutropenia: Decreases in white blood cell counts are common. A Complete Blood Count (CBC) must be monitored prior to starting therapy and every 2 weeks for the first 2 months of treatment.
Hepatotoxicity: Can cause elevated liver enzymes (ALT/AST). Liver function tests should be conducted regularly.
Venous Thromboembolism (VTE): Patients should be observed for signs of deep vein thrombosis (DVT) or pulmonary embolism, including leg swelling, chest pain, or sudden shortness of breath.
Special Populations
Pregnancy & Contraception: Abemaciclib can cause fetal harm. Female patients of childbearing potential must use highly effective contraception during treatment and for at least 3 weeks following the final dose.
Hepatic Impairment: For patients with severe hepatic impairment (Child-Pugh Class C), the dosing frequency should be adjusted downward to once daily.